x

Politics

Early Study Results Suggest 2 Ebola Drugs, One Developed by Regeneron, Saving Lives

August 14, 2019

WASHINGTON, DC – Two of four experimental Ebola drugs being tested in Congo seem to be saving lives, international health authorities announced on August 12.

The preliminary findings prompted an early halt to a major study on the drugs and a decision to prioritize their use in the African country, where a yearlong outbreak has killed more than 1,800 people.

The early results mark “some very good news,” said Dr. Anthony Fauci of the U.S. National Institutes of Health (NIH), which helped fund the study. With these drugs, “we may be able to improve the survival of people with Ebola.”

The two drugs — one developed by Regeneron Pharmaceuticals and the other by NIH researchers — are antibodies that work by blocking the virus. Greek-American Dr. George Yancopoulos is the President and Chief scientific officer of Regeneron and Dr. P. Roy Vagelos is the Chairman of the Board.

While research shows there is an effective albeit experimental vaccine against Ebola — one now being used in Congo — no studies have signaled which of several potential treatments were best to try once people became sick. During the West Africa Ebola epidemic several years ago, studies showed a hint that another antibody mixture named ZMapp worked, but not clear proof.

So with the current outbreak in Congo, researchers compared ZMapp to three other drugs — Regeneron’s compound, the NIH’s called mAb114, and an antiviral drug named remdesivir.

On Friday, independent study monitors reviewed how the first several hundred patients in the Congo study were faring — and found enough difference to call an early halt to the trial. The panel determined that the Regeneron compound clearly was working better than the rest, and the NIH antibody wasn’t far behind, Fauci explained. Next, researchers will do further study to nail down how well those two compounds work.

The data is preliminary, Fauci stressed. But in the study, significantly fewer people died among those given the Regeneron drug or the NIH’s — about 30% compared to half who received ZMapp. More striking, when patients sought care early — before too much virus was in their bloodstream — mortality was just 6% with the Regeneron drug and 11% with the NIH compound, compared to about 24% for ZMapp, he said.

Among people who receive no care in the current outbreak, about three-fourths die, said Dr. Michael Ryan of the World Health Organization. All of Congo’s Ebola treatment units have access to the two drugs, he added, saying he was hopeful that the news would persuade more patients to seek care — as soon as symptoms appear.

Tackling Congo’s outbreak has been complicated both by conflict in the region and because many people don’t believe Ebola is real and choose to stay at home when they’re sick, which spurs spread of the virus.

“Getting people into care more quickly is absolutely vital,” Ryan said. “The fact that we have very clear evidence now on the effectiveness of the drugs, we need to get that message out to communities.”

Fauci said Regeneron and Ridgeback Biotherapeutics, which has licensed the NIH compound, told authorities enough doses are readily available.

One issue researchers will have to analyze: Occasionally people who receive the Ebola vaccine still become sick, including some in the treatment study, which raises the question of whether their earlier protection inflated the drugs’ survival numbers.

(Material from the Associated Press was used in this report).

RELATED

ATHENS - A regulation in an omnibus bill will allow repatriated Greeks from Albania and the former Soviet Union to receive full national pensions, Labor and Social Protection Minister Kostis Hatzidakis said during a discussion in Greek Parliament on Tuesday.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Camels a Common Sight for World Cup Visitors (Photos + Video)

DOHA, Qatar — Two weeks into the first World Cup in the Middle East, fewer teams are at the tournament and some fans are starting to make long journeys home.

ATHENS - Once again this year, the Stavros Niarchos Foundation Cultural Center (SNFCC) was festooned with thousands of festive lights, transforming it into a magical Christmas World, through an exclusive grant from the Stavros Niarchos Foundation (SNF)! It all starts with a big celebration on Thursday, December 1 at 19:00.

NEW YORK — A man was wounded during an exchange of gunfire with New York City police officers in the Bronx, police said Sunday.

ATHENS - The government will officially announce on Monday a total of 68,000 new subsidized positions, Labor & Social Affairs Miniter Kostis Hatzidakis said on Sunday at an event in Thessaloniki.

ATHENS - Applications will open on Monday for staff ing 14,563 positions in the public sector through permanent or temporary transfers of already employed staff.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.